Overview

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Phase:
PHASE3
Details
Lead Sponsor:
Novartis Pharmaceuticals